These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 27486753)

  • 21. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
    Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
    Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting of BRM Sensitizes
    Zernickel E; Sak A; Riaz A; Klein D; Groneberg M; Stuschke M
    Mol Cancer Ther; 2019 Mar; 18(3):656-666. PubMed ID: 30478150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of the INI1 tumor suppressor does not impair the expression of multiple BRG1-dependent genes or the assembly of SWI/SNF enzymes.
    Doan DN; Veal TM; Yan Z; Wang W; Jones SN; Imbalzano AN
    Oncogene; 2004 Apr; 23(19):3462-73. PubMed ID: 14990991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features.
    Matsubara D; Kishaba Y; Ishikawa S; Sakatani T; Oguni S; Tamura T; Hoshino H; Sugiyama Y; Endo S; Murakami Y; Aburatani H; Fukayama M; Niki T
    Cancer Sci; 2013 Feb; 104(2):266-73. PubMed ID: 23163725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of extracellular matrix/adhesion molecule expression by BRG1 is associated with increased melanoma invasiveness.
    Saladi SV; Keenen B; Marathe HG; Qi H; Chin KV; de la Serna IL
    Mol Cancer; 2010 Oct; 9():280. PubMed ID: 20969766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The BRG1 ATPase of chromatin remodeling complexes is involved in modulation of mesenchymal stem cell senescence through RB-P53 pathways.
    Alessio N; Squillaro T; Cipollaro M; Bagella L; Giordano A; Galderisi U
    Oncogene; 2010 Oct; 29(40):5452-63. PubMed ID: 20697355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BRG1 knockdown inhibits proliferation through multiple cellular pathways in prostate cancer.
    Giles KA; Gould CM; Achinger-Kawecka J; Page SG; Kafer GR; Rogers S; Luu PL; Cesare AJ; Clark SJ; Taberlay PC
    Clin Epigenetics; 2021 Feb; 13(1):37. PubMed ID: 33596994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SWI/SNF complexes are required for full activation of the DNA-damage response.
    Smith-Roe SL; Nakamura J; Holley D; Chastain PD; Rosson GB; Simpson DA; Ridpath JR; Kaufman DG; Kaufmann WK; Bultman SJ
    Oncotarget; 2015 Jan; 6(2):732-45. PubMed ID: 25544751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors.
    Rodriguez-Nieto S; Cañada A; Pros E; Pinto AI; Torres-Lanzas J; Lopez-Rios F; Sanchez-Verde L; Pisano DG; Sanchez-Cespedes M
    Hum Mutat; 2011 Feb; 32(2):E1999-2017. PubMed ID: 21280140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation.
    Banine F; Bartlett C; Gunawardena R; Muchardt C; Yaniv M; Knudsen ES; Weissman BE; Sherman LS
    Cancer Res; 2005 May; 65(9):3542-7. PubMed ID: 15867346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncogene-dependent function of BRG1 in hepatocarcinogenesis.
    Wang P; Song X; Cao D; Cui K; Wang J; Utpatel K; Shang R; Wang H; Che L; Evert M; Zhao K; Calvisi DF; Chen X
    Cell Death Dis; 2020 Feb; 11(2):91. PubMed ID: 32019910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers.
    Sun A; Tawfik O; Gayed B; Thrasher JB; Hoestje S; Li C; Li B
    Prostate; 2007 Feb; 67(2):203-13. PubMed ID: 17075831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.
    Hoffman GR; Rahal R; Buxton F; Xiang K; McAllister G; Frias E; Bagdasarian L; Huber J; Lindeman A; Chen D; Romero R; Ramadan N; Phadke T; Haas K; Jaskelioff M; Wilson BG; Meyer MJ; Saenz-Vash V; Zhai H; Myer VE; Porter JA; Keen N; McLaughlin ME; Mickanin C; Roberts CW; Stegmeier F; Jagani Z
    Proc Natl Acad Sci U S A; 2014 Feb; 111(8):3128-33. PubMed ID: 24520176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1.
    Sánchez-Tilló E; Lázaro A; Torrent R; Cuatrecasas M; Vaquero EC; Castells A; Engel P; Postigo A
    Oncogene; 2010 Jun; 29(24):3490-500. PubMed ID: 20418909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased expression but not genetic alteration of BRG1, a component of the SWI/SNF complex, is associated with the advanced stage of human gastric carcinomas.
    Sentani K; Oue N; Kondo H; Kuraoka K; Motoshita J; Ito R; Yokozaki H; Yasui W
    Pathobiology; 2001; 69(6):315-20. PubMed ID: 12324708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic alterations of BRG1 leads to cancer development through its nuclear-cytoplasmic shuttling abnormalities.
    Gunduz E; Gunduz M; Nagatsuka H; Beder L; Demircan K; Tamamura R; Hatipoglu OF; Mahmut N; Katase N; Naomoto Y; Nagai N
    Med Hypotheses; 2006; 67(6):1313-6. PubMed ID: 16824695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression inactivation of SMARCA4 by microRNAs in lung tumors.
    Coira IF; Rufino-Palomares EE; Romero OA; Peinado P; Metheetrairut C; Boyero-Corral L; Carretero J; Farez-Vidal E; Cuadros M; Reyes-Zurita FJ; Lupiáñez JA; Sánchez-Cespedes M; Slack FJ; Medina PP
    Hum Mol Genet; 2015 Mar; 24(5):1400-9. PubMed ID: 25355421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome.
    Schneppenheim R; Frühwald MC; Gesk S; Hasselblatt M; Jeibmann A; Kordes U; Kreuz M; Leuschner I; Martin Subero JI; Obser T; Oyen F; Vater I; Siebert R
    Am J Hum Genet; 2010 Feb; 86(2):279-84. PubMed ID: 20137775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways.
    Jubierre L; Soriano A; Planells-Ferrer L; París-Coderch L; Tenbaum SP; Romero OA; Moubarak RS; Almazán-Moga A; Molist C; Roma J; Navarro S; Noguera R; Sánchez-Céspedes M; Comella JX; Palmer HG; Sánchez de Toledo J; Gallego S; Segura MF
    Oncogene; 2016 Sep; 35(39):5179-90. PubMed ID: 26996667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brg1 coordinates multiple processes during retinogenesis and is a tumor suppressor in retinoblastoma.
    Aldiri I; Ajioka I; Xu B; Zhang J; Chen X; Benavente C; Finkelstein D; Johnson D; Akiyama J; Pennacchio LA; Dyer MA
    Development; 2015 Dec; 142(23):4092-106. PubMed ID: 26628093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.